AMSTERDAM – New data on Albireo Pharma Inc.'s A-4250, an ileal bile acid transport inhibitor, has shown its capacity to reduce high levels of serum bile acids (sBA), which are often associated with severe itching, or pruritus, and liver damage in children with the rare cholestatic liver disease progressive familial intrahepatic cholestasis (PFIC).